Gerontology
Experimental Section
Memory Impairment Means Less Pain for MicePickering G. · Chapuy E. · Eschalier A. · Dubray C.INSERM EMI 9904, Clinical Pharmacology Department, University Hospital, Clermont-Ferrand, France
Keywords: HotplateScopolamineKetaminePainMemory |
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: March 07, 2003
Accepted: July 11, 2003
Published online: April 28, 2004
Issue release date: February 2004
Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 0
ISSN: 0304-324X (Print)
eISSN: 1423-0003 (Online)
For additional information: https://www.karger.com/GER
Abstract
Background: Clinical observations have reported that individuals with memory deterioration, like in Alzheimer’s disease, display a lesser pain sensibility than patients with no cognitive impairment. Objective: To clarify the link between pain and loss of memory, we studied how memory-impaired mice behave when submitted to hotplate nociceptive tests. Methods: For 5 days (D1–D5), male CD1 mice were injected daily intraperitonealy with saline or scopolamine (s, an anticholinergic drug, 0.2 mg/kg) or ketamine (k, an N-methyl-D-aspartate receptor antagonist (NMDAr), 2.5 mg/kg), at doses leading to memory impairment with no analgesic effect. From D6 to D9, all received saline only. They were placed on the hotplate and removed at the first sign of discomfort, response time being recorded. Results: From D1 to D5, reaction time decreased significantly in controls only and did not change in mice with scopolamine or ketamine. From D6 to D9, response times decreased (p < 0.05 (s) and p < 0.0001 (k)) to reach the steady state of control animals. At D5, response time was significantly prolonged for scopolamine (p < 0.01) and ketamine (p < 0.05), compared to controls. Conclusion: These results show that pain sensibility needs the integrity of the central cholinergic and of the NMDA systems, and that mice with memory impairment display a lesser pain sensibility than normal mice. Further research on the complex interactions of receptors and neurotransmitters involved in pain and cognition could assist in gaining a better understanding of pain and analgesia in patients with memory impairment and in demented individuals.
© 2004 S. Karger AG, Basel
Related Articles:
References
-
Bartolini L, Casamenti F, Pepeu G: Aniracetam restores object recognition impaired by age, scopolamine and nucleus basalis lesions. Pharmacol Biochem Behav 1996;53:277–283.
- Begon S, Pickering G, Eschalier A, Mazur A, Rayssiguier Y, Dubray C: Role of spinal NMDA receptors, protein kinase C and nitric oxide synthase in the hyperalgesia induced by magnesium deficiency in rats. Br J Pharmacol 2001;134:1227–1236.
-
Benedetti F, Vighetti S, Ricco C, Lagna E, Bergamasco B, Pinessi L, Rainero I: Pain threshold and tolerance in Alzheimer’s disease. Pain 1999;80:377–382.
- Bruins Slot LA, Colpaert FC: Opiate states of memory. J Neurosci 1999;19:10520–10529.
- Cain DP, Ighanian K, Boon F: Individual and combined manipulation of muscarinic, NMDA and benzodiazepine receptor activity in the water maze task: Implications for a rat model of Alzheimer dementia. Behav Brain Res 2000;111:125–127.
- Colpaert F, Bruins Slot LA, Koek W, Dupuis DS: Memory of an operant response and of depressed mood retained in activation states of 5-HT1A receptors: Evidence from rodent models. Behav Brain Res 2000;117:41–51.
- Daniel JM, Dohanich GP: Acetylcholine mediates the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and the associated improvement in working memory. J Neurosci 2001;21:6949–6956.
- Dodart JC, Mathis C, Ungerer A: Scopolamine-induced deficits in a two-trial object recognition task in mice. Neuroreport 1997;8:1173–1178.
- Frampton M: Experience assessment and management of pain in people with dementia. Age Ageing 2003;32:248–251.
-
Gagliese L, Melzack R: Age differences in nociception and pain behaviours in the rat. Neurosci Behav Rev 2000;24:843–854.
-
Hasselmo ME: Neuromodulation: Acetylcholine and memory consolidation. Trends Cogn Sci 1999;3:351–359.
- Inan SY, Aksu F, Baysal F: The effects of some K(+) channel blockers on scopolamine- or electroconvulsive shock-induced amnesia in mice. Eur J Pharmacol 2000;407:159–164.
- Jourdan D, Pickering G, Marchand F, Gaulier JM, Alliot J, Eschalier A: Impact of ageing on the antinociceptive effect of reference analgesics in the Lou/c rat. Br J Pharmacol 2002;137:813–820.
- Kovalev GV, Sazhin VA, Kuleshova IP: Pharmacological correction of ketamine-impaired spatial memory of rats. Biull Eksp Biol Med 1990;110:618–620.
- Lai YY, Chan SHHH: Shortened pain response time following repeated algesiometric test in rats. Physiol Behav 1982;28:1111–1113.
-
Li HB, Matsumoto K, Tohda M, Yamamoto M, Watanabe H: NMDA antagonists potentiate scopolamine-induced amnesic effect. Behav Brain Res 1997;83:225–228.
- Li Z, Wu CF, Pei G, Xu NJ: Reversal of morphine-induced memory impairment in mice by withdrawal in Morris water maze. Possible involvement of cholinergic system. Pharmacol Biochem Behav 2001;68:507–513.
- Mishima K, Tsukikawa H, Inada K, Fujii M, Iwasaki K, Matsumoto Y, Abe K, Egawa T, Fujiwara M: Ameliorative effect of vasopressin through vasopressin V1A receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze. Eur J Pharmacol 2001;427:43–52.
- Pepeu G: Overview and perspectives on the therapy of Alzheimer’s disease from a clinical viewpoint. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:193–209.
-
Pfenninger EG, Durieux ME, Himmelseher S: Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. Anesthesiology 2002;96:357–366.
-
Pickering G, Eschalier A, Dubray C: Pain and Alzheimer’s disease. Gerontology 2000;46:235–241.
- Pickering G, Jourdan D, Eschalier A, Dubray C: Impact of age, gender and cognitive functioning on pain perception. Gerontology 2002;48:112–118.
- Pitsikas N, Rigamonti AE, Cella SG, Locatelli V, Sala M, Muller EE: Effects of molsidomine on scopolamine-induced amnesia and hypermotility in the rat. Eur J Pharmacol 2001;426:193–200.
-
Plone MA, Emerich DF, Linder MD: Individual differences in the hotplate test and effects of habituation on sensitivity to morphine. Pain 1996;66:265–270.
- Rolandi E, Gandolfo C, Franceschini R, Cataldi A, Garibaldi A, Barreca T: Twenty-four-hour β-endorphin secretory pattern in Alzheimer’s disease. Neuropsychobiology 1992;25:188–192.
- Sandkühler J, Treier AC, Liu XG, Ohnimus M: The massive expression of c-fos protein in spinal dorsal horn neurons is not followed by long-term changes in spinal nociception. Neuroscience 1996;73:657–666.
-
Scherder EJ, Bouma A: Is decreased use of analgesics in Alzheimer’s disease due to a change in the affective component of pain? Alzheimer’s Dis Assoc Disord 1997;11:171–174.
-
Scherder EJ, Bouma A: Acute versus chronic pain experience in Alzheimer’s disease. A new questionnaire. Dement Geriatr Cogn Disord 2000;11:11–16.
External Resources
-
Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ: Genetic enhancement of learning and memory in mice. Nature 1999;40:63–69.
- Wei F, Wang GD, Kerchner GA, Kim SJ, Xu HM, Chen ZF, Zhuo M: Genetic enhancement of inflammatory pain by forebrain NR2B overexpression. Nat Neurosci 2001;4:164–169.
-
Woolfe G, MacDonald AD: The evaluation of the analgesic action of pethidine hydrochloride (Demerol). J Pharmacol Exp Ther 1944;80:300–307.
-
Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983;16:109–110.
Article / Publication Details
Received: March 07, 2003
Accepted: July 11, 2003
Published online: April 28, 2004
Issue release date: February 2004
Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 0
ISSN: 0304-324X (Print)
eISSN: 1423-0003 (Online)
For additional information: https://www.karger.com/GER
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
